Sisonke Study News Today

Once more we find Karim’s presence and influence in these organisations that led our understanding of Covid-19 and the official response.

Saimbarashe Takuva, Azwi Takalani, and colleagues investigate the frequency and incidence of adverse events reported after receipt of a single dose of the Ad26.COV2.S COVID-19 vaccine among health care workers in South Africa.

The Sisonke study team is launching the Sherpa Study that will assess the Moderna booster in protecting against COVID-19 infections and severe COVID-19 disease among healthcare workers.

A new study shows that people who receive a second dose of the Johnson & Johnson Covid-19 vaccine are less likely to end up in hospital for the disease.

A new study shows that people who receive a second dose of the Johnson & Johnson (J&J) Covid-19 vaccine are less likely to end up in hospital for the disease.   The study, published in the New England Journal of Medicine by the Sisonke Study team, is one of the first real-world studies on vaccine effectiveness against the Omicron variant of the virus that causes Covid-19.

Sisonke Programme researchers gave an update on recent findings, saying less than half of the studys first phase participants had been administered booster shots.

Currently, a booster shot of the Johnson & Johnson vaccine is only being administered to health care workers under the Sisonke Study

The dedicated trial opened on 10 November, but so far only around 200,000 healthcare workers have come forward.

The South African Health Products Regulatory Authority (SAHPRA) and Johnson & Johnson (J&J) on Friday approved vaccine booster doses for all h

Vaccinated healthcare workers are once again at risk of contracting Covid-19 — and even dying — because the efficacy of the Johnson & Johnson vaccine is fast beginning to wane.